Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03969K108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| BlackRock, Inc. 13G/A Amendment 2 | 14.1% |
10/5/2026
Event 9/30/2026
|
|
|
Polar Capital Holdings Plc
13G
|
5.3% |
8/14/2026
Event 6/30/2026
|
|
| Polar Capital Holdings Plc | 5.3% | ||
| Polar Capital LLP | 5.3% | ||
| State Street Corp 13G | 4.7% |
8/7/2026
Event 6/30/2026
|
|
| State Street Corp 13G | 5.1% |
5/12/2026
Event 3/31/2026
|
|
| Prudential Financial Inc 13G/A Amendment 4 | 4.3% |
5/8/2026
Event 3/31/2026
|
|
| Jennison Associates LLC 13G/A Amendment 5 | 4.0% |
5/6/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
| Prudential Financial Inc 13G/A Amendment 3 | 5.7% |
2/13/2026
Event 12/31/2025
|
|
|
Rubric Capital Management LP
13G/A
Amendment 2
|
6.8% |
2/13/2026
Event 12/31/2025
|
|
| Rubric Capital Management LP | 6.8% | ||
| David Rosen | 6.8% | ||
| Jennison Associates LLC 13G/A Amendment 4 | 5.5% |
1/30/2026
Event 12/31/2025
|
|
| Jennison Associates LLC 13G/A Amendment 3 | 10.2% |
10/6/2025
Event 9/30/2025
|
|
|
Frazier Life Sciences VIII, L.P.
13D/A
Amendment 7
|
7.5% |
8/20/2025
Event 8/18/2025
|
|
| Frazier Life Sciences VIII, L.P. | 7.3% | ||
| FHM Life Sciences VIII, L.P. | 7.4% | ||
| FHM Life Sciences VIII, L.L.C. | 7.4% | ||
| Frazier Life Sciences X, L.P. | 0% | ||
| FHMLS X, L.P. | 0% | ||
| FHMLS X, L.L.C. | 0% | ||
| Frazier Life Sciences Public Fund, L.P. | 0.6% | ||
| FHMLSP, L.P. | 0.6% | ||
| FHMLSP, L.L.C. | 0.6% | ||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.2% | ||
| FHMLSP Overage, L.P. | 0.2% | ||
| FHMLSP Overage, L.L.C. | 0.2% | ||
| Frazier Life Sciences XI, L.P. | 0.1% | ||
| FHMLS XI, L.P. | 0.1% | ||
| FHMLS XI, L.L.C. | 0.1% | ||
| Frazier Life Sciences XII, L.P. | 0.1% | ||
| FHMLS XII, L.P. | 0.1% | ||
| FHMLS XII, L.L.C. | 0.1% | ||
| James N. Topper | 7.4% | ||
| Patrick J. Heron | 7.5% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 3
|
4.2% |
8/14/2025
Event 6/30/2025
|
|
| Polar Capital Holdings Plc | 4.2% | ||
| Polar Capital LLP | 4.2% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 4.2% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 2
|
5.7% |
5/15/2025
Event 3/31/2025
|
|
| Polar Capital Holdings Plc | 5.7% | ||
| Polar Capital LLP | 5.7% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 5.1% | ||
| Prudential Financial Inc 13G/A Amendment 2 | 10.1% |
5/15/2025
Event 3/31/2025
|
|
| Jennison Associates LLC 13G/A Amendment 1 | 9.6% |
5/8/2025
Event 3/31/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 7 | 13.4 k | $355 k |
| 2026 Q2 | 281 | 135 M | $3.57 B |
| 2026 Q1 | 280 | 133 M | $3.13 B |
| 2025 Q4 | 294 | 129 M | $3.75 B |
| 2025 Q3 | 252 | 126 M | $2.37 B |
| 2025 Q2 | 245 | 130 M | $1.82 B |
| 2025 Q1 | 254 | 126 M | $1.97 B |
| 2024 Q4 | 220 | 129 M | $1.80 B |
| 2024 Q3 | 199 | 130 M | $1.21 B |
| 2024 Q2 | 199 | 132 M | $1.23 B |
| 2024 Q1 | 178 | 134 M | $1.33 B |
| 2023 Q4 | 142 | 108 M | $349 M |
| 2023 Q3 | 146 | 67.1 M | $357 M |
| 2023 Q2 | 152 | 71.8 M | $685 M |
| 2023 Q1 | 153 | 71.6 M | $797 M |
| 2022 Q4 | 153 | 69.8 M | $1.03 B |
| 2022 Q3 | 148 | 59.7 M | $1.14 B |
| 2022 Q2 | 127 | 49.3 M | $1.05 B |
| 2022 Q1 | 115 | 48.7 M | $937 M |
| 2021 Q4 | 100 | 46.4 M | $962 M |
| 2021 Q3 | 109 | 45.7 M | $1.09 B |
| 2021 Q2 | 110 | 45.7 M | $1.25 B |
| 2021 Q1 | 98 | 46.8 M | $1.35 B |
| 2020 Q4 | 80 | 41.0 M | $1.15 B |
| 2020 Q3 | 65 | 34.8 M | $1.02 B |
| 2020 Q2 | 57 | 33.8 M | $1.02 B |
| 2020 Q1 | 52 | 32.7 M | $974 M |